Skip to main content
Premium Trial:

Request an Annual Quote

SeqWright to Take Stake in LaserGen

NEW YORK (GenomeWeb News) – SeqWright is set to make an undisclosed equity investment in LaserGen, a Houston-based developer of chemistries for next-generation sequencing applications.

LaserGen said that SeqWright's decision to invest was prompted by LaserGen's plans to commercialize its reversible terminator chemistry, called Lightning Terminators, for next-generation sequencing applications. The firm said that its technology can increase the speed, throughput, and read length of next-generation sequencing, while lowering cost, by attaching a special terminating group directly to the base, which frees up the 3'-hydroxyl group.

LaserGen said that it would bring the Lightning Terminators chemistry to market as reagent kits as early as next year, and that it expects to form strategic partnerships with existing next-generation instrument manufacturers. It believes SeqWright can help it achieve that goal.

Further terms of the investment or collaboration with SeqWright were not disclosed.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.